Squarepoint
ONCT

Squarepoint’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Squarepoint’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-878
Closed -$40K – 3716
2021
Q4 		$40K Buy
+878
New +$59.1K ﹤0.01% 3055
2021
Q1 		– Sell
-849
Closed -$83K – 3756
2020
Q4 		$83K Buy
+849
New +$53.7K ﹤0.01% 2747
2018
Q2 		– Sell
-130
Closed -$324K – 2128
2018
Q1 		$324K Buy
+130
New +$290K 0.01% 1286

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Squarepoint's ONCT Position: Q1 2022 in Review

Squarepoint sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2022, closing a stake of 878 shares — an estimated $40K sold.

Squarepoint first reported a position in ONCT in Q1 2018 and held it in 3 quarters. The position peaked at $324K in Q1 2018. 78 funds tracked by Wall St. Rank hold ONCT as of Q1 2022.

  • Squarepoint reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Squarepoint sold 878 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $40K.
  • Squarepoint first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
  • Squarepoint's Oncternal Therapeutics, Inc. Common Stock position peaked at $324K in Q1 2018.
  • 78 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Squarepoint's 13F filing for Q1 2022, filed 16 May 2022.